Navigation Links
TorreyPines Therapeutics Reports Third Quarter 2007 Results
Date:11/14/2007

and pharmacokinetics of tezampanel

given once-daily for four consecutive days. Data from this multiple

dose trial are intended to support the continued development of

tezampanel for the treatment of migraine, as well as allow TorreyPines

to consider expanding the development of tezampanel into additional

chronic pain conditions.

-- Completed a Phase I multiple-dose clinical trial of NGX267 in

development for cognitive impairment associated with schizophrenia

(CIAS). NGX267 was found to be safe and well-tolerated. The clinical

trial also demonstrated that NGX267 increases salivary flow, which may

be beneficial in treating xerostomia, or dry mouth.

-- Extended the genetics discovery collaboration with Eisai Co., Ltd.

This agreement focuses on the discovery of Alzheimer's disease targets

using whole-genome family-based association screening. Under terms of

the agreement, TorreyPines received an upfront payment and continued

research funding in support of the program for an additional year.

Financial Results

Revenue for the three month period ended September 30, 2007 was $2.5 million compared to revenue of $2.5 million for the same period in 2006. Operating expenses for the quarter ended September 30, 2007 were $9.5 million, with $8.2 million attributable to research and development. This compares to operating expenses of $5.2 million and research and development expenses of $4.5 million for the same period last year. The Company reported a net loss for the quarter ended September 30, 2007 of $6.8 million compared to a net loss of $2.7 million for the same period last year.

Revenue for the nine month period ended September 30, 2007 was $7.4 million compared to revenue of $7.4 million for the same period in 2006. Operating expenses for the nine month period were $24.6 million, with $20.4 million attributabl
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
2. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
3. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
4. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
5. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Delaware , August 3, 2015 ... in the commercialization of its Bio-electrical Signal Therapy device ... noninvasive treatment of hard to heal chronic wounds, today ... agreement with Chemipal, an Israeli distributor specializing in medical ... device. Chemipal is a 70 years old, ...
(Date:8/3/2015)... NEW YORK , August 3, 2015 ... "Global Market Study on 3D Cell Culture: ... published by Persistence Market Research, the global 3D cell culture ... is expected to expand at a CAGR of 29.1% ... View Full Report with TOC:  http://www.persistencemarketresearch.com/market-research/3d-cell-cultures-market.asp ...
(Date:8/3/2015)... ... 2015 , ... Sterlitech Corporation introduces the compact, quiet, and ... laboratory equipment. With optimized features, such as PTFE-coated contact surfaces, an oil-free design, ... solution for a broad range of vacuum filtration applications. , Featuring a 1/7 ...
(Date:7/31/2015)... ... 2015 , ... Global Resorcinol Market 2015-2019 is a comprehensive ... global resorcinol industry. The report highlights the various growth prospects and the prevalent ... of primary and secondary inputs from the existing players of the resorcinol market. ...
Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 2Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 3Global 3D Cell Culture Market Will Reach US$ 2,717.6 Million by 2020: Persistence Market Research 4Sterlitech Launches New Line of Vacuum Pumps 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4
... three DFG Research Centres will again be extended and ... made by the Joint Committee of the Deutsche Forschungsgemeinschaft ... Bonn. As a result, the Research Centres established in ... Center for Functional Nanostructures" in Karlsruhe, and "Research Center ...
... (Nasdaq: TPTX ) today reported financial results for ... For the three-month period, the company posted a net loss ... million at March 31, 2009.On April 15, 2009, the Company ... in the evaluation of strategic options, including the possible sale ...
... YORK and NASSAU, The Bahamas, May 1 Fincor ... Prospero Group (Pink Sheets: PRPG) , a leading company ... the new ACTRx Malaria and Dengue fever treatment. Fincor also ... a majority of ACTRx International Inc., which combines several natural ...
Cached Biology Technology:The first DFG research centers to be funded for another 4 years 2The first DFG research centers to be funded for another 4 years 3The first DFG research centers to be funded for another 4 years 4TorreyPines Therapeutics Reports First Quarter 2009 Financial Results 2TorreyPines Therapeutics Reports First Quarter 2009 Financial Results 3TorreyPines Therapeutics Reports First Quarter 2009 Financial Results 4Fincor (FINC) Makes a Share Transfer and Enters the Market With ACTRx a New Malaria and Dengue Fever Treatment 2
(Date:7/8/2015)... 2015 Summary Pancreatic cancer is the ... fatal, with a mortality rate of 10.9 deaths per ... cancer patients has highlighted a significant need for new ... met by the current market. A highly active ... varying molecule types and mechanisms of action, which provides ...
(Date:7/7/2015)... 7, 2015  Based on its recent analysis ... recognizes Credence ID, LLC with the 2015 Asia-Pacific ... the Year Award. Credence ID has developed a ... mission of offering enrollment and identification solutions to ... ID was formed by experts from the mobile ...
(Date:6/30/2015)... NEW YORK , June 30, 2015 To ... biometric security provider HYPR Corp. announced today the addition of ... will serve as board advisor and David Raviv ... to the team underscore HYPR Corp.,s commitment to providing the ... , Dimitri Sirota co-founded Layer 7 Technologies, a ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3
... in Spanish . Obese men should ... scientist told the 24th annual conference of the European Society ... A Ghiyath Shayeb, from the University of Aberdeen, Aberdeen, UK, ... higher body mass index (BMI) had lower volumes of seminal ...
... Lauderdale, FL (July 8, 2008) Scientists announced today ... size of the Southern Atlantic Ocean,s largest and richest ... of Brazil,s Bahia state. The newly discovered ... than the previously known Abrolhos reef system, one of ...
... to a new location or go extinct as a result ... in Northern England seem to defy the odds and adapt ... new study by scientists from Syracuse University and the University ... issue of the Early Edition of the Proceedings of ...
Cached Biology News:Obese men have less semen, more sperm abnormalities, and should lose weight before trying for a baby 2Scientists discover new reefs teeming with marine life in Brazil 2New study finds that some plants can adapt to widespread climate change 2